Determinants of Myelosuppression in the Treatment of Non-small Cell Lung Cancer with Cisplatin-containing Chemotherapy |
| |
Authors: | Kaoru Matsui Noriyuki Masuda Yasuo Uchida Masahiro Fukuoka Shunichi Negoro Takashi Yana Yoko Kusunoki Shinzoh Kudoh Ichiro Kawase Masaaki Kawahara Mitsumasa Ogawara Nagahisa Kodama Kaoru Kubota Kiyoyuki Furuse |
| |
Institution: | 2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital, 3-7-1 Habikino, Habikino, Osaka 583;Scientific Affairs Department, Pharmaceuticals Group, Nippon Kayaku Co., Ltd., 11-2, Fujimi 1-chome, Chiyoda-ku, Tokyo 102;Department of Internal Medicine, National Kinki Central Hospital, 1180 Nagasone, Sakai, Osaka 591 |
| |
Abstract: | Data on 16 potential risk factors for myelosuppression were assessed in 134 patients who received either vindesine and cisplatin (VP) or mitomycin C, vindesine and cisplatin (MVP) for inoperable stage III or IV non-small cell lung cancer in a randomized trial. Determinant factors for myelosuppression were evaluated by using univariate analysis and the logistic regression model. Recursive partitioning and amalgamation (RPA) was also used to define patient subgroups frequently suffering from severe bone marrow toxicity. Overall, 33 (25%) of 134 patients experienced at least one episode of grade 4 leukopenia. In univariate analysis, age, body surface area, serum creatinine, and pretreatment hemoglobin concentration were associated with severe leukopenia. A multivariate analysis using the logistic regression method showed that only raised creatinine level was an independent predictor for grade 4 leukopenia ( P =0.049). The RPA model generated three distinct subgroups based on age, body surface area and regimen. The three subgroups were distinguished by the frequency of severe (grade 4) leukopenia (50%, 25%, and 2.4%, respectively) ( P <0.001). Grade 4 leukopenia occurred more frequently in patients in class 3 (age ≥65 years and treatment with MVP). The RPA model was useful in identifying the risk factors for myelosuppression induced by cisplatin-based chemotherapy, and in defining patient subgroups with elevated risk of toxicity. |
| |
Keywords: | Cisplatin-based chemotherapy Non-small cell lung cancer Bone marrow suppression Elderly patient Recursive partitioning and amalgamation |
|
|